SCHEMBL1663760

SCHEMBL1663760

CCCC(N)CCC(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.70
ENPEP Q07075 6/20 0.61
ANPEP P15144 3/20 0.61
GABRP O00591 2/20 0.56
GABRD O14764 2/20 0.56
GABRA1 P14867 2/20 0.56
GABRB1 P18505 2/20 0.56
GABRG2 P18507 2/20 0.56
GABRB3 P28472 2/20 0.56
GABRA5 P31644 2/20 0.56
GABRA3 P34903 2/20 0.56
GABRA2 P47869 2/20 0.56
GABRB2 P47870 2/20 0.56
GABRA4 P48169 2/20 0.56
GABRE P78334 2/20 0.56
GABRA6 Q16445 2/20 0.56
GABRG1 Q8N1C3 2/20 0.56
GABRG3 Q99928 2/20 0.56
GABRQ Q9UN88 2/20 0.56
S1PR2 O95136 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL289090 0.87 ENPEP (0.76) ALDH1A1ENPEPANPEPGABRPGABRD
SCHEMBL289085 0.86 ALDH1A1 (0.66) ALDH1A1ENPEPANPEPGABRPGABRD
SCHEMBL157617 0.86 ALDH1A1 (0.66) ALDH1A1ENPEPANPEPGABRPGABRD
SCHEMBL466531 0.86 ALDH1A1 (0.85) ALDH1A1ENPEPMEN1TSHRKMT2A
SCHEMBL8509937 0.85 ALDH1A1 (0.69) ALDH1A1ENPEPANPEPS1PR2S1PR1
SCHEMBL1877095 0.85 ALDH1A1 (0.69) ALDH1A1ENPEPANPEPS1PR2S1PR1
SCHEMBL1873964 0.85 ALDH1A1 (0.96) ALDH1A1ENPEPMEN1TSHRKMT2A
SCHEMBL288475 0.83
SCHEMBL900872 0.83
SCHEMBL5194202 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1380064-A Method for producing antibiotic preparation and its application HERAEUS GUSA GMBH & CO KG (DE) 2002-11-20 CN claimed
CN-110072883-A The relevant peptide of therapeutic MOTS-C 科巴公司 2019-07-30 CN disclosed
US-20190046600-A1 COMPOSITIONS AND USES THEREOF WARENIUS HILMAR M (GB) 2019-02-14 US disclosed
EP-3414326-A1 COMPOSITIONS AND USES THEREOF Warenius, Hilmar M (GB) 2018-12-19 EP disclosed
US-20170313746-A1 Peptides Useful For Treating Cancer WARENIUS HILMAR M (GB) 2017-11-02 US disclosed
WO-2017137761-A1 COMPOSITIONS AND USES THEREOF WARENIUS HILMAR M (GB) 2017-08-17 WO disclosed
EP-3177716-A1 PEPTIDES USEFUL FOR TREATING CANCER Warenius, Hilmar M (GB) 2017-06-14 EP disclosed
WO-2016020437-A1 PEPTIDES USEFUL FOR TREATING CANCER WARENIUS HILMAR M (GB) 2016-02-11 WO disclosed
EP-2305282-B1 Prevention and treatment of amyloidogenic disease JANSSEN ALZHEIMER IMMUNOTHERAP (IE) 2013-07-10 EP disclosed
WO-2011086565-A1 METHOD FOR PREPARATION OF ENANTIOMERICALLY ENRICHED AND/OR RACEMIC GAMMA-AMINO ACIDS LUPIN LIMITED (IN) 2011-07-21 WO disclosed
EP-0738154-A1 N-TERMINUS MODIFIED ANALOGS OF LHRH Abbott Laboratories (US) 1996-10-23 EP disclosed
EP-0738154-A4 N-TERMINUS MODIFIED ANALOGS OF LHRH ABBOTT LAB (US) 1996-04-12 EP disclosed
US-5502035-A N-terminus modified analogs of LHRH TAP HOLDINGS INC. (US) 1996-03-26 US disclosed
EP-0592732-B1 Liquid transfer tube NITTA MOORE CO LTD (JP) 1995-12-27 EP disclosed
WO-1995004541-A1 N-TERMINUS MODIFIED ANALOGS OF LHRH ABBOTT LABORATORIES (US) 1995-02-16 WO disclosed
US-5330810-A Liquid transfer tube NITTA MOORE COMPANY (JP) 1994-07-19 US disclosed
EP-0592732-A1 Liquid transfer tube NITTA MOORE COMPANY (JP) 1994-04-20 EP disclosed
US-4957980-A POLYAMIDE-POLYESTER BLEND, COMPATIBILIZING AGENT TOYO BOSEKI KABUSHIKI KAISHA (JP) 1990-09-18 US disclosed
US-4812163-A Phenoxyacetic acids and herbicides comprising them as active ingredients TEIJIN, LIMITED (JP) 1989-03-14 US disclosed
US-4398642-A MULTILAYER; THERMOPLASTIC POLYESTERS AND POLYAMIDES LAYERS TOYO BOSEKI KABUSHIKI KAISHA (JP) 1983-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190046600-A1 COMPOSITIONS AND USES THEREOF LDHA, PARP1, LDHB ALDH1A1 58/4885ENPEP 857/4885ANPEP 2635/4885
US-20170313746-A1 Peptides Useful For Treating Cancer PARP1, PARP3, LNPEP ALDH1A1 2496/4885ENPEP 24/4885ANPEP 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.